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Abstract: Carbamazepine (CBZ), a pharmaceutical compound, has been proposed as an
anthropogenic marker to assess water quality due to its persistence in conventional treatment
plants and widespread presence in water bodies. This paper presents a comprehensive literature
review on sources and occurrences of CBZ in water bodies, as well as toxicological effects and
regulations of the drug. Given the documented side effects of CBZ on the human body when
taken medicinally, its careful monitoring in water is recommended. CBZ residues in drinking
water may provide a pathway to embryos and infants via intrauterine exposure or breast-feeding,
which may cause congenital malformations and/or neurodevelopmental problems over long term
exposure. An in-depth technical assessment of the conventional and advanced treatment technologies
revealed the inadequacy of the standalone technologies. Compared to conventional activated sludge
and membrane bioreactor processes, effective removal of CBZ can be achieved by nanofiltration
and reverse osmosis membranes. However, recent studies have revealed that harsh chemical
cleaning, as required to mitigate membrane fouling, can often reduce the long-term removal
efficiency. Furthermore, despite the efficient performance of activated carbon adsorption and
advanced oxidation processes, a few challenges such as cost of chemicals and regeneration of
activated carbon need to be carefully considered. The limitations of the individual technologies point
to the advantages of combined and hybrid systems, namely, membrane bioreactor coupled with
nanofiltration, adsorption or advanced oxidation process.
Keywords: advanced oxidation processes (AOPs); activated carbon adsorption; carbamazepine toxicity;
conventional treatment processes; membrane technology; occurrence
1. Introduction
The occurrence of pharmaceutically active compounds (PhACs) in environmental systems such
as freshwater bodies has become a topic of growing concern over the last decade due to their
Water 2018, 10, 107; doi:10.3390/w10020107 www.mdpi.com/journal/water
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potential detrimental impacts on aquatic life and human health [1,2]. Because a large proportion
of PhACs ends up in sewage via bodily excretion and indiscriminate disposal of unwanted/expired
pharmaceuticals, disposal of untreated or ineffectively treated wastewater is considered a major source
of their occurrence in environmental systems [3–6]. The need for effective removal of PhACs has
resulted in the emergence of various advanced wastewater treatment technologies such as membrane
technology and advanced oxidation processes [4].
The widespread occurrence of PhACs in wastewater and wastewater-impacted freshwater has
triggered the establishment of water quality standards for their regular monitoring [5,7]. In this context,
carbamazepine (CBZ) has been proposed as an anthropogenic marker of sewage contamination in
freshwater bodies [8,9]. CBZ is an anticonvulsant and mood stabilizing drug used primarily in the
treatment of epilepsy and bipolar disorder [10]. Table 1 summarizes the salient physicochemical
properties of CBZ. CBZ is one of the most frequently detected pharmaceutical compounds in
environmental systems [4,11]. It is ubiquitously present in raw wastewater in the high ng/L to
low µg/L range and is only poorly removed by the conventional wastewater treatment plants
(WWTP) [12,13]. Almost all the known advanced technologies have been tested for CBZ removal,
however, none has appeared as a universal solution [14,15].
Table 1. Physicochemical and pharmacological properties of carbamazepine (modified after [16,17]).
Structure
Water 2018, 10, x FOR PEER REVIEW  2 of 31 
 
potential de rimental impacts on aquatic life and human health [1,2]. Because a large proportion of 
PhACs ends up in sewage via bodily excretion and indiscriminate disposal of unwanted/expired 
pharmaceuticals, disposal of untreated or ineffectively treated wastewater is considered a major 
source of their occurrence in environmental systems [3–6]. The need for effective removal of PhACs 
has resulted in the emergence of various advanced wastewater treatment technologies such as 
membra e technology nd advanced oxidation processes [4]. 
The widespread occurrence of PhACs in wastewater and wastewater-impacted freshwater has 
triggered the establishment of water quality standards for their regular monitoring [5,7]. In this 
context, carbamazepine (CBZ) has been proposed as an anthropogenic marker of sewage 
contamination in freshwater bodies [8,9]. CBZ is an anticonvulsant and mood stabilizing drug used 
primar ly in the treatment of epil psy and bipolar disorder [10]. Table 1 summarizes the salient 
physicochemical properties of CBZ. CBZ is one of the most frequently detected pharmaceutical 
compounds in environmental systems [4,11]. It is ubiquitously present in raw wastewater in the high 
ng/L to low µg/L range and is only poorly removed by the conventional wastewater treatment 
plants (WWTP) [12,13]. Almost all the known advanced technologies have been tested for CBZ 
removal, however, none has appeared as a universal solution [14,15]. 
Table 1. Physicochemical and pharmacological properties of carbamazepine (modified after [16,17]). 
Structure 
 
 
Formula C15H12N2O 
CAS No. 298-46-4 
Molecular Weight 236.2686 g·mol−1 
Usage Anticonvulsant/mood stabilizing drug 
Water solubility 17.7 mg/L (25 °C) 
Log P (octanol-water partition coefficient) 2.45 
Log D at pH = 7 a 1.32 
Henry’s Law Constant 1.09 × 10−5 Pa·m3·mol−1 (25 °C) 
Half-life (t1/2) 25–65 h 
Excretion 72% absorbed and metabolized in liver, 28% excreted in feces 
Metabolites in urine CBZ, CBZ-epoxide, CBZ-diol, CBZ-acridan,  
2-OH-CBZ, 3-OH-CBZ 
Dosage 800–1200 mg/day 
Other information Autoinduction i.e., induces its own  
metabolism during continued intake 
Note: a Log D is the logarithm of the distribution coefficient, which is the ratio of the sum of concentrations 
of all forms of the compound (ionised and unionised) in octanol and water at a given pH [3]. 
A number of interesting review papers have been published on the occurrences of micropollutants 
in environmental systems such as wastewater [18], surface water [4] and groundwater [5], as well as the 
performance of conventional treatment technologies for the removal of micropollutants [19–21]. The 
persistence of CBZ in conventional treatment processes leads to its widespread occurrence in water 
bodies. Thus, CBZ has been proposed as an anthropogenic marker to assess water treatment quality. 
CBZ removal by conventional WWTPs has been reviewed previously by Zhang et al. [16]. However, the 
efficacy of advanced treatment technologies has not been critically analyzed to date. In addition, toxicity 
of CBZ to aquatic species and human and relevant regulations have not been comprehensively 
reviewed. 
In this paper, the occurrence of CBZ in wastewater and freshwater bodies (e.g., surface and 
groundwater) along with the associated influencing factors are systematically analyzed. In addition, 
the toxicological effects of CBZ on the aquatic ecosystem are critically discussed. Importantly, the 
Formula C15 N2O
CAS No. 298-46-4
Molecular Weight 236.2686 g·mol−1
Usage Anticonvulsant/mood stabilizing drug
Water solubility 17.7 mg/L (25 ◦C)
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A number of interesting review papers have been published on the occurrences of micropollutants
in environmental systems such as wastewater [18], surface water [4] and groundwater [5], as well as
the performance of conventional treatment technologies for the removal of micropollutants [19–21].
The persistence of CBZ in conventional treatment processes leads to its widespread occurrence in water
bodies. Thus, CBZ has been proposed as an anthropogenic marker to assess water treatment quality.
CBZ removal by conventional WWTPs has been reviewed previously by Zhang et al. [16]. However,
the efficacy of advanced treatment technologies has not been critically analyzed to date. In addition, toxicity
of CBZ to aquatic species and human and relevant regulations have not been comprehensively reviewed.
In this paper, the occurrence of CBZ in wastewater and freshwater bodies (e.g., surface and
groundwater) along with the associated influencing factors are systematically analyzed. In addition,
the toxicological effects of CBZ on the aquatic ecosystem are critically discussed. Importantly,
the factors governing the resistance of CBZ to the available wastewater treatment processes are
elucidated, and the efficacy of advanced/emerging treatment processes is comprehensively discussed.
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2. Occurrence in Aquatic Systems
Following consumption, up to 10% of CBZ is excreted from human body [4,22]. Recent studies
have reported a few tens to several thousands of ng/L CBZ in municipal wastewater [22–24].
CBZ is poorly removed (typically less than 10%) by the conventional WWTPs [25–27]. Hence,
treatment plant effluents are an important gateway for CBZ to enter surface and groundwater.
Table 2 depicts the reported levels of occurrence of CBZ in WWTP effluent, surface water and
groundwater. Generally, CBZ concentration has been reported to be higher in WWTP effluents as
compared to surface water (Table 2) because dilution and natural attenuation can significantly reduce
the concentration of pollutants [28]. CBZ is most likely to reach groundwater via bank infiltration
of WWTP effluent [5,29]. In addition, seepage of landfill leachate and combined sewer overflows
can contaminate groundwater [30]. In this section, the factors influencing the occurrence of PhACs
including CBZ in raw wastewater, WWTP effluent and freshwater bodies are critically discussed.
Table 2. Occurrences of carbamazepine (CBZ) in municipal wastewater treatment plant (WWTP)
effluent and freshwater.
Country W WWTP Effluent Surface Water Groundwater
No. of WWTPs * Concentration (ng/L) Concentration (ng/L) Concentration (ng/L)
Canada 7 33–426 [a] 0.7–126 [b] 10–49 [c]
Germany 5 1075–6300 [d] 81–1100 [e] 1–100 [f]
Japan 20 81–86 [g] 0.1–34.7 [h] 1.64–97 [i]
South Korea 11 73–729 [j] 6–61 [k] NA
Taiwan 4 290–960 [l] 0.5–120 [m] NA
UK 3 152–4596 [n] 9–327 [o] 425–3600 [p]
USA 16 33–270 [q] 2–172 [r] 1.5–42 [s]
Notes: Data sources: [a] [31–34]; [b] [31,32,35]; [c] [36,37]; [d] [29,38–40]; [e] [38,40,41]; [f] [42,43]; [g] [44–46]; [h] [45,
47]; [i] [46,47]; [j] [48,49]; [k] [48–51]; [l] [52,53]; [m] [52]; [n] [54–56]; [o] [54,55,57,58]; [p] [30,59,60]; [q] [28,61–63];
[r] [61,63–65]; [s] [66,67]. * number of WWTPs surveyed for analyzing the concentration of CBZ; NA: not available.
2.1. Wastewater Treatment Plant Effluent
Since a number of factors can affect CBZ occurrence in wastewater, its concentration in WWTP
effluent has been observed to be highly variable (30–6300 ng/L) (Table 2). The variation in WWTP
effluent CBZ concentration (Tables 2 and 3) can be attributed to a number of factors such as CBZ
production/consumption rate, environmental regulations, effectiveness of the WWTPs and the
seasonal factors affecting WWTP performance [4,68,69].
Table 3. Seasonal variations in CBZ concentration along with its annual consumption rate.
Country
WWTP Effluent Consumption Rate
(tons/year)
No. of WWTPs*
Concentration (ng/L)
Winter Summer
Australia 3 1480 [70] NA 10 [16]
Austria
11 952 [71] 1337–1594 [3,71]
6 [16]11 1000 [72] 1500 [72]
Canada 4 426 [32] 300 [33] 28 [16]
Finland
12 500 [6] NA
4.8 [16]3 380–470 [73] NA
Germany 3 1900 [38] 2100 [40] 76 [16]
Korea 4 103–195 [48] 5–6 [48] 9.2 [48]
Switzerland
2 1000 [74] 950 [74]
4.1 [75]3 400–800 [26] 200–600 [26]
UK 3 (Winter)2 (Summer) 637–950 [56] 2499 [54] 40 [16]
Note: * Number of WWTPs surveyed for analyzing the concentration of CBZ in winter and summer; NA: not available.
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Some studies have reported good correlation between CBZ concentration in wastewater with its
production and consumption rate at the corresponding locations. For instance, Kasprzyk-Hordern et al. [22]
and Choi et al. [48] studied the occurrence of PhACs such as carbamazepine, acetaminophen,
sulfamethoxazole and codeine in wastewater from selected locations of UK and Korea, respectively.
They observed that the concentration of pharmaceuticals in wastewater correlated well with their
consumption rates in the respective countries [22,48]. By contrast, CBZ concentration in the WWTP
effluent of Canada, Finland and Switzerland (Table 3) did not correlate well with CBZ consumption rates,
indicating that there are other influencing factors.
PhAC occurrence in wastewater can be governed by, among other factors, their excretion rate
after metabolism within human body. However, it is important to note that low excretion rate from
human body does not necessarily lead to their detection in low concentration or frequency in water.
For instance, excretion rate of CBZ and a few other PhACs such as ibuprofen, clofibric acid and
gemfibrozil is generally low (1–10%), while excretion rates of up to 70% were reported for some PhACs
such as atenolol and paracetamol [76,77]. However, as noted above, CBZ is detected in significantly
high concentration in raw and treated wastewater because of its low removal by the natural attenuation
process and by the WWTPs [4,78].
Seasonal variations that affect the flow pattern of wastewater in combined sewerage system
can lead to the change in wastewater composition. In a study by Kasprzyk-Hordern et al. [22],
an increase of up to two-folds in the concentration of PhACs including CBZ was observed during
dry weather. Moreover, WWTP effluent CBZ concentration in some countries such as Australia [70],
Switzerland [26,74] and USA [79] were reported to be consistently higher in winter than in summer
(Table 3), which can also be attributed to drier weather conditions in winter [22,26].
2.2. Surface Water
The major source of CBZ in surface water is the disposal of WWTP effluent [80,81]. After its release
to freshwater bodies, different natural attenuation processes such as photolysis, aerobic biodegradation,
sorption onto sediments and dilution in surface water play an important role in reducing CBZ
concentration [81,82]. However, in-stream attenuation rate varies depending on the physicochemical
properties of the PhACs and the local environmental conditions. For instance, Kunkel and Radke [83]
observed different attenuation rates for 10 pharmaceuticals including CBZ in river water, and this
variation was generally attributed to the physicochemical properties of the compounds. Similarly,
in a study that investigated the relationship between attenuation rate and physicochemical properties
of 225 micropollutants [82], high attenuation rate was obtained for compounds having medium to
low volatility (−4 < log Kaw < −2) and significant hydrophilicity (0 < log Kow < 4.5). This is because
these micropollutants are better exposed to in-stream biotic (e.g., biotransformation) and abiotic
(e.g., photolysis) attenuation processes as compared to hydrophobic micropollutants that are adsorbed
onto river sediments [84]. Since log Kow value for CBZ falls between 0-4.5 [17,81], its concentration is
expected to be reduced via in-stream attenuation processes [85].
Water dilution can reduce CBZ concentration in surface water. Indeed, higher concentrations
of PhACs including CBZ was reported in surface water bodies during dry weather as compared to
that observed in wet weather [86]. In a study by Wang et al. [87], CBZ concentration in surface water
was lower in samples that were collected during summer than those collected during winter. This is
probably because of the enhanced biodegradation rate due to higher temperature in summer [4,81].
Heavy rainfall can often cause increased leaching of PhACs from openly dumped municipal and
hospital solid waste. Storm water runoff can lead these compounds to surface water, consequently
increasing the concentration of PhACs in surface water [23,88].
Sorption onto river sediments has been reported to reduce the aqueous phase concentration of
hydrophobic PhACs along the river segment. However, in this case, concentration of these pollutants is
not significantly reduced by the in-stream biotic and abiotic attenuation processes [81,84,89]. In a study
by Riml et al. [90], concentration of two PhACs, namely bezafibrate and metoprolol, was observed to
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be mainly reduced by sorption onto sediments, while the role of biotransformation and photolysis
was insignificant. Since it is a moderately hydrophobic compound (log Kow = 2.45), reduction in CBZ
concentration has been attributed to photolysis and sorption [85,91].
Residues of CBZ are introduced into sea water via surface runoff and groundwater discharge [92].
Concentrations of CBZ in sea water are very low. Weigel et al. [93] detected CBZ in sea water
at a concentration of 2 ng/L by using a method that comprised solid-phase extraction and GC/MS
quantification with a detection limit of 0.1 and 0.7 ng/L. Although this value seems insignificant, the fact
that CBZ is detectable in sea water indicates that it is an extremely persistent compound. Also interesting
to note, is that residues of CBZ can accumulate in soil through seepage of irrigation water, and due
to sewage sludge used as fertilizer [94,95]. A study conducted by the US Geological Survey found an
average CBZ concentration of 41.6 ng/mg in the sediment of 44 rivers across the US [96].
2.3. Groundwater
Groundwater constitutes approximately 30% of the total freshwater resources in the world.
Because 70% of the freshwater resources are frozen, groundwater represents 97% of freshwater available
for human use [97]. Groundwater is the major source of freshwater for domestic and industrial use in
many countries. PhACs can contaminate groundwater through different pathways such as percolation
of landfill leachate, artificial recharge, percolation of storm water runoff and leakages from sewers
and septic tanks [5]. Depending on the organic fraction of the soil, high attenuation of some PhACs
such as hydrophobic compounds (log D > 3) can occur in soil strata en route to groundwater [98,99].
Nevertheless, CBZ concentration in groundwater has been reported to be in the range of 1–100 ng/L in
available studies from Canada, Germany, Japan and USA (Table 2). However, a higher concentration
of CBZ (425 to 3600 ng/L) in groundwater was observed at a site in UK [30,59,60]. This is probably
because CBZ concentration was also higher in WWTP effluents and surface water in that location
(Tables 2 and 3). Indeed, Stuart et al. [30] reported that the occurrence of CBZ in groundwater is most
likely to be derived from the bank infiltration of WWTP effluent or through surface water/groundwater
interaction. Concentration of CBZ in groundwater may not be as high as in surface water but it is still
an issue that should be addressed on a priority basis.
3. Toxicological Effects
CBZ is widely detected in water bodies, hence it is essential to evaluate its effects on the ecosystems.
A number of studies have assessed the ecotoxicity of CBZ (Table 4). In an experiment conducted
by Ying et al. [25], the respiratory quotient value for CBZ was 4.69, indicating potential risks to
aquatic organisms. However, other experimental studies have shown that CBZ may not pose an
immediate risk. For example, Ferrari et al. [100] studied the toxicological effects of CBZ on bacteria,
algae, microcrustaceans and fish. It was observed to have a relatively limited acute ecotoxicity on the
tested organisms.
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Table 4. Effect of CBZ exposure on aquatic species under different exposure conditions.
Species Critical Effects Exposure Time LC50 (mg/L) EC50 (mg/L) NOEC (mg/L) LOEC (mg/L) References
Water flea
Daphnia magna Mortality 2 days 111 - - - [101]
Chironomus dilutus Survival 10 days 47.3 10.2 - - [102]
Hyalella azteca Growth 10 days 1.5 9.5 - - [102]
Brachionus calyciflorus Reproduction inhibition 2 days - - 0.4 0.8 [100]
Ceriodaphnia dubia Reproduction inhibition 7 days - - 0.025 0.1 [100]
Daphnia magna Mobility inhibition 2 days - 77.7 - - [100]
Daphnia magna Immobilization 2 days - 97.8 - - [103]
Bacteria
Aliivibrio fischeri Bioluminescence 30 min - 64.2 - - [100]
Vibrio fischeri Bioluminescence 5 min - 87.4 - - [103]
Algae
Chlorella vulgaris Growth inhibition 24 h - 110.9 - - [103]
Desmodesmus
subspicatus Inhibition of average growth rate 3 days - 74 - - [104]
Raphidocelis subcapitata Growth inhibition 4 days 89 >100 >100 [100]
Rainbow trout
Oncorhynchus mykiss Condition factor 42 days - - - 2 [105]
Oncorhynchus mykiss Antioxidant responses in muscle 42 days - - - 0.001 [105]
Oncorhynchus mykiss Changes in RNA-DNA ratio 42 days - - - 2 [105]
Zebrafish
Danio rerio Developmental effects 3 days >245 85.6 30.6 - [106]
Danio rerio Embryos and larvae mortality 10 days - - 25 50 [100]
Mycorrhizal fungus
Glomus intraradices Spore production 28 days - 0.1 - - [107]
Duckweed
Lemna minor Inhibition of average growth rate 7 days - 25.5 - - [104]
Cnidarian
Hydra attenuate Morphological changes 4 days 29.4 15.5 1 5 [108]
Notes: LC50: lethal concentration to kill/inactivate 50% of population; EC50: effective concentration that gives half-maximal response; NOEC: no-observed effect concentration; and LOEC:
lowest-observed effect concentration. “-”: not available.
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Possible human health effects of long-term exposure to different pharmaceuticals may
include endocrine disruption, induction of antibiotic resistance in human pathogens, genotoxicity,
carcinogenicity, allergic reactions, and reproductive and/or developmental effects [109,110].
Limited research has been conducted on the potential human health risks of long-term exposure
to CBZ residues in water. Risk assessments conducted to date have generally shown that the trace
concentrations of CBZ detected in drinking water does not pose an unacceptable health risk to
humans [111]. However, careful monitoring must continue, given the documented side effects of CBZ
on the human body when taken medicinally.
CBZ is the main cause of the Stevens–Johnson syndrome and its associated disease toxic epidermal
necrolysis in Southeast Asian countries due to its intake medicinally [112]. These are two forms of
a life-threatening skin condition with an overall mortality rate of 30%, in which cell death causes
the epidermis to separate from the dermis [113]. Recent studies have also revealed that intrauterine
exposure of CBZ is associated with spina bifida [114] and neuro developmental problems [115]
of human embryo when gravidas were exposed to CBZ monotherapy. Atkinson et al. [116] also
reported higher fetal losses and congenital malformation rates among women who were prescribed
carbamazepine during pregnancy. Because the residue of CBZ in drinking water may provide
a pathway to embryo and infant via intrauterine exposure or breast-feeding, the presence of CBZ in
groundwater, and drinking water remains a significant concern warranting further systematic risk
assessment studies.
4. Regulations
Strict regulations were introduced in the 1960s in many countries for pharmaceutical
production [117]. For example, in Australia, the Therapeutic Goods Administration (TGA) undertakes
assessments, similar to those of the US Food and Drug Administration (FDA), to “ensure that
prescription and ‘over-the-counter’ medicines, medical devices, and related products, supplied in or
exported from Australia, meet appropriate standards” [118].
Despite the release of a significant amount of PhACs into the environment, there is limited literature
available on regulations for the presence of pharmaceuticals in water [117]. The regulatory framework set
out for pharmaceuticals governs the quality and safety of use, rather than the health and environmental risks
of long-term exposure to drinking water containing trace concentrations of pharmaceuticals. In the U.S.,
the FDA requires that an environmental assessment report be carried out when the expected concentration
of the active ingredient of the pharmaceutical in the aquatic environment is equal to or higher than 1 µg/L.
However, some state departments, such as the Minnesota Department of Health regulates that the CBZ
concentration in drinking water must not exceed 40 µg/L [119]. Australian regulations require CBZ
concentration in drinking water to be less than 100 µg/L [120]. In Europe, authorization for pharmaceutical
production requires an environmental risk assessment [118]. In many countries, however, health risk-based
standards and limit values for the presence of pharmaceuticals in drinking water have either not been set
or are insufficient [111].
5. Biological Treatment Technologies for CBZ Removal
5.1. Activated Sludge Based Processes
Removal of PhACs by different biological treatment processes has been studied extensively [3,4].
In conventional activated sludge (CAS) processes, microorganisms generate energy by utilizing bulk
organics present in wastewater as a primary source of food (also known as substrate). A part of this
energy is used by the microorganisms for their cell growth and remaining energy is used for cell
maintenance [121–123]. Since some PhACs such as antibiotics can be toxic to microorganisms and
can inhibit their growth, an additional growth substrate (i.e., co-metabolism) is required to maintain
microbial growth and diversity for adequate biodegradation [124,125].
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The CAS process involves the application of microorganisms for the degradation of pollutants [16].
A membrane bioreactor (MBR) is an integration of the CAS process with an ultrafiltration (UF) or
a microfiltration (MF) membrane for effective solid-liquid separation [3,126,127]. Removal of CBZ
by CAS and MBR at different operating conditions such as hydraulic retention time (HRT), solids
retention time (SRT) and initial concentration is presented in Table 5.
Table 5. CBZ removal by conventional activated sludge (CAS) and membrane bioreactor (MBR) under
different operating conditions.
Process
Type
Influent
Concentration (ng/L) SRT (days) HRT (h) Aerobic/Anoxic Removal (%) References
CAS
240 3 12 aerobic negligible [128]
156 10 11.5 both negligible [126]
350–1850 52–114 12.5–13.6 both negligible [71]
350 2–20 1.5–20 both negligible [6]
15–270 3.8–8.4 7.1–9.4 aerobic negligible–80 [129]
1000 10 7.3 both negligible [74]
670–704 19 NA aerobic 0 [130]
10–20 11–15 9–17 both negligible–25 [131]
200–600 15–25 16–24 aerobic negligible [132]
MBR
240 infinite 14 aerobic negligible [128]
156 >60 15 aerobic negligible [126]
156 >60 7.2 aerobic negligible [126]
704–1850 10–55 0.5–4 both negligible [71]
1000 16 13 both 25 [74]
704–1200 22 NA both negligible [130]
750,000 infinite 24 near-anoxic 68 [133]
5 88 26 aerobic 40 [27]
1400 70 24 aerobic 10 [134]
Notes: CAS: conventional activated sludge process; MBR: membrane bioreactor; SRT: solid retention time; HRT:
hydraulic retention time; NA: not available.
In the CAS process, a settling tank is used to separate the treated water from the sludge. In MBR,
this solid-liquid separation is performed by filtration via MF or UF membranes. Effective retention
of the activated sludge by the membrane in MBR decouples SRT from HRT, thereby allowing the
operation of the activated sludge based bioreactor at higher mixed liquor suspended solid concentration
(MLSS) and longer SRT [135,136]. It has been reported in several studies that MBR provides better
aqueous phase removal of moderately biodegradable PhACs as compared to the CAS process [126,137].
For example, removal of the nonsteroidal anti-inflammatory drug diclofenac by MBR was 56%,
while its removal was 26% in CAS [138]. Similarly, MBR achieved up to 20% better removal of another
nonsteroidal anti-inflammatory drug naproxen [126]. However, CBZ removal by both CAS and MBR
has been reported to be poor and unstable (Table 5). Poor removal of CBZ can be attributed to its
physicochemical properties such as molecular structure and hydrophilicity [71,134,139,140].
Sorption onto the activated sludge can increase the overall removal of PhACs. CAS and MBR
are observed to achieve high removal (>80%) for hydrophobic PhACs (log D > 3) but lower removal
(typically < 20%) for hydrophilic PhACs [141,142]. Since CBZ is moderately hydrophobic, its removal via
sorption onto activated sludge has been reported to range between 5 to 20% only [16,27]. This suggests
that CBZ removal depends on its intrinsic biodegradability, which is governed by its molecular properties.
In general, simple structured PhACs, especially without branched/multi chain groups, are readily
degradable [134,143]. Moreover, PhACs containing an electron withdrawing functional group (EWG), such
as carboxyl, halogen and amide, are resistant to biological treatment [134]. Indeed, CBZ contains an EWG
(i.e., amide) that makes it resistant to biodegradation.
It is important to note that operating conditions such as SRT, HRT and MLSS concentration can
also influence the removal of some PhACs by activated sludge [3,139]. However, because CBZ is
a hardly biodegradable compound, available reports indicate limited influence of these parameters on
CBZ removal. Zhang et al. [16] did not observe any CBZ removal by CAS even at an SRT of 100 days.
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Similarly, Radjenovic et al. [128], observed no improvement in CBZ removal following the increase in
the SRT of both CAS and MBR. By contrast, Wijekoon et al. [27] achieved 40% removal of CBZ in MBR
at a SRT of 88 days. Notwithstanding the fact that the experimental conditions may have been different
in these studies, the observations here suggest that the removal and fate of CBZ during biological
treatment processes depend on multiple factors.
The effect of redox conditions or dissolved oxygen on the removal of PhACs in MBR has been
reported in a few studies [144–146]. In a study by Suarez et al. [147], PhACs were classified based
on their biodegradation potential under aerobic and anoxic conditions: they observed that readily
degradable PhACs such as fluoxetine and ibuprofen were biodegradable under both anoxic and aerobic
conditions, while a few such as roxithromycin, naproxen, diclofenac and erythromycin were persistent
in anoxic conditions but highly biodegradable under aerobic conditions. However, hydrophilic
PhACs including CBZ were resistant to biodegradation in both aerobic and anoxic conditions [147],
and a negligible difference in CBZ removal by sequential anoxic—aerobic MBR versus conventional
aerobic MBR was noted. Notably, however, Hai et al. [139] reported that near-anoxic conditions
(DO = 0.5 mg/L) can be a favorable operating regime for CBZ removal. They explained that ‘sequential
anoxic-aerobic’ and ‘continuous near-anoxic (DO = 0.5 mg/L)’ operation modes were different.
In the former, oxygen transfer from the aerated compartments to the anoxic zone due to the sludge
recirculation may influence the removal efficiency [139].
5.2. White-Rot Fungi and Their Extracellular Enzymes
White-rot fungi (WRF) can degrade a variety of recalcitrant pollutants (e.g., poly-aromatic
hydrocarbons and PhACs) that are poorly degraded by bacteria-dominated activated sludge [148–152].
In presence of a readily degradable substrate, WRF produce one or more type of extracellular enzymes such
as laccase and lignin peroxidases (LiP). These enzymes catalyze the degradation of recalcitrant pollutants
over a wide range of pH [153,154]. In addition to the extracellular enzymes, Golan-Rozen et al. [155]
observed that the intracellular enzyme viz cytochrome P450 plays a vital role in CBZ degradation by
whole-cell WRF. They demonstrated that the degradation of CBZ reduced from 99% to approximately
15% when cytochrome P450 was inhibited [155]. Whole-cell WRF and their extracellular enzymes have
been studied extensively for enhanced removal of PhACs as depicted in Table 6.
Table 6. Removal of CBZ by white-rot fungi and their extracellular enzymes.
Bioreactor Type WRF Species/EnzymeType
HRT
(h)/Incubation
Time (days)
Initial
Concentration
(ng/L)
Removal
Efficiency (%) References
Removal by whole-cell WRF
Stirred tank (batch) Bjerkanderasp. R1 14 1,000,000 99 [156]
Stirred tank
(batch)
B. adusta
(Laccase, LiP and MnP) 14 1,000,000 99 [156]
Stirred tank
(batch)
T. versicolor
(Laccase, LiP and MnP) 2 10,000 75 [157]
Stirred tank
(batch)
T. versicolor
(Laccase, LiP and MnP) 1 100,000 2 [158]
Stirred tank
(batch)
P. ostreatus (Florida N001)
(Laccase, MnP) 32 1000 50 [155]
Stirred tank
(batch)
P. ostreatus (Florida F6)
(Laccase, MnP) 32 1000 60 [155]
Stirred tank
(batch)
P. ostreatus (PC9)
(Laccase, MnP) 32 1000 99 [155]
Stirred tank a
(continuous)
P. chrysosporium
(MnP, LiP) 24 500,000 25–60 [159]
Fluidized bed a
(continuous)
T. versicolor (Laccase,
MnP, LiP) 72 200,000 95.6 [160]
Membrane bioreactor
(continuous) a
T. versicolor
(Laccase, MnP, LiP) 48 5000 20 [161]
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Table 6. Cont.
Bioreactor Type WRF Species/EnzymeType
HRT
(h)/Incubation
Time (days)
Initial
Concentration
(ng/L)
Removal
Efficiency (%) References
Removal by extracellular enzymes
Stirred tank
(batch)
Laccase from
A. oryzae 1 100,000 <5 [162]
Stirred tank
(batch)
Laccase from
T. versicolor 2 10,000 5 [157]
Stirred tank
(batch)
LiP from
P. chrysosporium 4 NA 10–15 [163]
Membrane bioreactor
(continuous)
Laccase from
A. oryzae 8 5000 <5 [162]
Membrane bioreactor
(continuous)
Laccase from
A. oryzae 8 5000 7 [164]
Notes: a Indicates fungal bioreactor operated under non-sterile conditions; NA: not available.
Depending on the fugal species, efficient removal of CBZ has been achieved by whole-cell
WRF in sterile batch bioreactors (Table 6). Since WRF species produce different combinations of
extracellular enzymes, their performance of CBZ degradation might be different. For instance,
Rodarte-Morales et al. [156] observed that Bjerkandera sp. R1 and Bjerkandera adusta both achieved almost
complete removal (99%) of CBZ at an initial concentration of 1 mg/L in a batch bioreactor over an
incubation time of 14 days. On the other hand, Trametes versicolor was reported to achieve less than 5%
removal when CBZ was incubated in a whole-cell batch bioreactor at an initial concentration of 0.1 mg/L
and an incubation time of 24 h [158]. Difference in performance was not only observed in case of different
WRF species but also in different strains of a WRF species. For instance, Golan-Rozen et al. [155] studied
the removal of CBZ by three different strains of Pleurotus ostreatus under identical operating conditions.
They observed that P. ostreatus (PC9) achieved 99% CBZ removal, while a moderate removal (50–60%) was
achieved by other two strains, namely P. ostreatus (Florida N001) and P. ostreatus (Florida F6).
Extracellular enzymes produced by WRF species have been studied for the removal of PhACs
including CBZ in both batch and continuous-flow enzymatic bioreactors (Table 6). Degradation of
PhACs by extracellular enzymes such as laccase occurs due to the transfer of a single electron from
the pollutant to the active sites of the enzyme. Similar to the activated sludge based treatment
process, the extent of degradation by an enzyme also depends on the molecular properties of
the PhACs. Since CBZ contains a recalcitrant EWG (i.e., amide), its degradation by extracellular
enzymes has been reported to range only between 5–15% [157,162]. High removal of CBZ in
whole-cell fungal bioreactor as compared to enzymatic membrane bioreactor was explained by
Golan-Rozen et al. [155]. They observed that the intracellular enzyme viz cytochrome P450 plays
a vital role in CBZ degradation by whole-cell WRF. They demonstrated that the degradation of CBZ
reduced from 99% to approximately 15% when cytochrome P450 was inhibited [155].
Performance of WRF for PhAC removal has been predominantly assessed under sterile conditions
to avoid bacterial contamination [158,165,166]. This is because bacterial contamination under
non-sterile conditions can negatively affect the performance of whole-cell WRF [154,167]. Indeed,
poor removal of CBZ has been reported in fungal bioreactors operated under non-sterile conditions
as compared to sterile fungal bioreactors [168–170]. For instance, Nguyen et al. [161] reported only
5% CBZ removal in a whole-cell fungal membrane bioreactor. In another study, no CBZ removal
was observed in a non-sterile fluidized bed fungal bioreactor during the treatment of hospital
wastewater [171]. To avoid bacterial contamination, a number of strategies such as fungal biomass
replacement/renovation and pre-treatment of wastewater have been proposed. These strategies have
been reviewed by Asif et al. [154].
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6. CBZ Removal by Advanced Physicochemical Treatment Technologies
6.1. Performance of Nanofiltration and Reverse Osmosis Membranes
Nanofiltration (NF) and reverse osmosis (RO) are pressure-driven membrane filtration
technologies [172,173]. They utilize semi-permeable membranes to primarily target the removal of
dissolved contaminants. Both NF and RO have been studied for the removal of PhACs from secondary
treated wastewater and freshwater, producing excellent quality effluent [173–175]. Several studies
have shown that both NF and RO membranes can effectively retain CBZ, with a typical removal
efficiency of greater than 95% [176,177]. Table 7 illustrates representative examples of CBZ removal by
NF/RO membranes under a wide range of operating conditions.
Table 7. CBZ removal from various water matrices by nanofiltration (NF) and reverse osmosis (RO)
membranes under different operating conditions.
Membrane
Type (Pore
Size)
Configuration Water Matrix
Initial CBZ
Concentration
(ng/L)
Applied
Pressure
(psi)
Removal
(%) References
NF (0.34 nm) Flat-sheet Groundwater 84.5 NA >98 [176]
NF (0.27 nm) Flat-sheet (tight) MBR permeate 150 150 97.3 ± 0.6 [178]
NF (0.42 nm) Flat-sheet (loose) MBR permeate 150 75 71.2 ± 3.1 [178]
NF Flat-sheet WWTP effluent 500–850 4.35 6 [179]
NF Flat-sheet WWTP effluent 500–850 10 8 [179]
NF (0.84 nm) Flat-sheet Primary effluent 2000 72 74 [180]
NF Spiral-wound Hospitalwastewater 1000 98 88 [181]
NF (0.84 nm) Flat-sheet Syntheticwastewater 750,000 261 80
a, 60 b [182]
NF (0.68 nm) Flat-sheet Syntheticwastewater 750,000 261 95
a, 90 b [182]
NF (0.84 nm) Flat-sheet Syntheticwastewater 750,000 986 70
a, 20 b [183]
NF (0.84 nm) Flat-sheet Syntheticwastewater 750,000 261 80
a, 90 b [184]
RO (0.34 nm) Flat-sheet Groundwater 84.5 NA >98 [176]
RO Flat-sheet MBR permeate 150 250 91 ± 8.4 [178]
RO Flat-sheet MBR permeate 150 150 97.9 ± 1.5 [178]
RO Flat-sheet Primary effluent 1000 72 100 [180]
RO Spiral-woundmodule
Hospital
wastewater 1000 196 99 [181]
Notes: a Virgin membrane; b fouled membrane; NA: not available.
Conceptually, NF membranes can retain PhACs via following mechanisms: (i) sorption of a solute
on the membrane surface; (ii) size exclusion i.e., the sieving property of the membrane; and (iii) charge
repulsion. However, electrostatic interaction cannot contribute to CBZ removal by the charged NF
membrane, since CBZ remains neutral over a wide range of pH [14]. Hence, the molecular weight
cut-off (MWCO) of NF/RO membranes is an important parameter for CBZ removal. In a study by
Bellona et al. [177], efficient retention of CBZ by the RO membrane was attributed to size exclusion
mechanism because the molecular weight of CBZ (i.e., 236 g/mole) was greater than the MWCO of the
RO membrane. In a study by Comerton et al. [178], a loose NF membrane (MWCO = 400 g/mole) and
a tight NF (MWCO = 200 g/mole) achieved 7 and 67% CBZ removal, respectively, thus, exemplifying
the role of membrane MWCO in CBZ removal. In another study by Nghiem & Hawkes [185], efficient
rejection of CBZ was reported for the NF90 membrane (MWCO < 200 g/mole) as compared to the
NF270 membrane (MWCO > 300 g/mole).
Membrane fouling can affect the rejection of PhACs by NF membranes due to change in membrane
surface properties (Table 7). Notably, CBZ rejection by the NF membranes is governed by the type
of foulants. For instance, CBZ rejection by the NF270 membrane was reduced by 5 and 10% due to
fouling caused by humic acid and sodium alginate, respectively [186]. This reduction in CBZ removal
can be attributed to its diffusion into permeate following its adsorption on the fouling layer formed
on the membrane surface. A more dramatic reduction in CBZ rejection (by 50%) was reported when
MBR permeate (comprising multiple foulant materials) was fed to the NF-filtration system [186,187].
In general, the combination of membrane fouling and scaling can affect pollutant removal more
severely. Chemical cleaning is performed to clean fouled membranes. However, recurrent chemical
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cleaning can affect membrane properties and, in turn, CBZ rejection. For example, significant reduction
in CBZ rejection was observed due to cleaning the NF membrane by using caustic soda [184].
Natural organic matter (NOM) are ubiquitously present in surface water bodies. Since NF/RO
processes are widely used for surface water treatment [188], the effectiveness of NF/RO for CBZ
rejection in presence of NOM is vital. Comerton et al. [189] observed a statistically significant
improvement in CBZ rejection during nanofiltration of pure water spiked with NOM. This is
because CBZ, which is a moderately hydrophobic compound, can adsorb on NOM. However,
a significant decrease in the rejection of CBZ was observed with concentration of the cations (calcium,
magnesium, sodium) doubled. It has been hypothesized that increases in ionic strength and divalent
cation concentration can cause conformational changes to NOM macromolecules. This may alter
the presentation of sites for compound association leading to a reduction in NOM–compound
complexation [189]. Therefore, the decrease in CBZ rejection in the natural waters with increase
in cation concentration may be due to reduced association of CBZ with NOM.
6.2. Adsorption of CBZ by Activated Carbon
Activated carbons including granular activated carbon (GAC) and powdered activated carbon
(PAC) are widely used as tertiary treatment processes primarily for color and odor removal
from drinking water. GAC and PAC have also shown great potential for the removal of
PhACs from secondary (i.e., biologically treated) wastewater [4,190,191]. Adsorption/removal of
a pollutant by GAC/PAC is governed by the following mechanisms: (i) the electron donor–acceptor
complex; (ii) the π–π dispersion interactions; (iii) hydrophobic interactions; and (iv) solvent effects that
controls the solubility, reactivity and reaction kinetics [192,193]. The key properties of an adsorbent
that can affect the efficacy of adsorption process include but are not limited to surface area, dose,
surface chemistry and morphology, while water partitioning coefficient (log Kow), acid dissociation
coefficient (pKa), molecular structure and size of the pollutants can influence the extent of adsorption
by GAC/PAC [194]. In previous studies, efficient removal of PhACs has been achieved by GAC having
larger pore size, because it can effectively adsorb pollutants with different shapes and size. Moreover,
it was noted that pore volume has more influence on the adsorption of PhACs than specific area,
and larger pore volume can achieve higher removal efficiency [195,196]. Representative examples of
CBZ removal by GAC/PAC from a variety of water matrix (e.g., surface water and MBR effluent) is
provided in Table 8.
Table 8. Performance of granular activated carbon (GAC) and powdered activated carbon (PAC) for
CBZ removal from various water matrices.
AC
Type Water Matrix
Initial CBZ
concentration
(ng/L)
Contact
Time (min)
Removal
(%) References
GAC
Synthetic wastewater 1000 1440 99–80 a [197]
Ozonation effluent 36 – 88 b [198]
Groundwater 9 15 >75 c [199]
Surface water 25 – 99 [200]
Disinfected surface water 600 1.5–3 79 d [201]
WWTP effluent 67 – 30 e [202]
GAC added to an activated sludge based bioreactor 22,000 1440 43 f [203]
WWTP effluent 4000 100 80 g [204]
WWTP effluent 30–100 130 >99 [190]
PAC
Surface water 78 300 95 h [205]
Surface water 78 300 36 i [205]
MBR permeate 1000 30 99.4 j [206]
Surface water 50 240 80 [207]
WWTP effluent 30–100 20–40 95–100 [190]
Notes: a The specific throughput of CBZ in a carbon layer of 80 cm was 50 m3/kg when removal decreased to 80%;
b the daily production of this drinking water treatment plant was 28,000 m3, and this removal was observed in winter;
c the system comprised 20 granular activated filters (volume = 150 m3 each), experimental duration was 4 months;
d the daily production of this drinking water treatment plant was 235,000 m3 (experimental duration = 3 weeks); e total
GAC volume was 1900 m3; f the GAC concentration in the bioreactor was 1000 ppm, and experimental duration was
33 days; g the initial GAC concentration was 20 mg/L; h the PAC dose was 35 mg/L; i the PAC dose was 5 mg/L;
and j the PAC dose was 10 g/L, “–”: not available.
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Since CBZ is neutral at pH ranging from 0–14, its removal by activated carbon is governed by
hydrophobic interaction that depends on water partitioning coefficient [4,17]. In a study Yu et al. [17],
better adsorption of CBZ (log Kow = 2.45) by activated carbon as compared to naproxen (log Kow = 3.18)
and 4-n-nonylphenol (log Kow = 5.8) was reported. Better adsorption of CBZ can be attributed to
influence of pH on hydrophobicity of ionizable micropollutants [3]. Indeed, Yu et al. [17] demonstrated
that activated carbon achieved better CBZ (log Kow = 2.45) removal as compared to naproxen
because actual log Kow value for naproxen was 0.89 at the operating pH (i.e., 6.4). On the other
hand, 4-n-nonylphenol contains both hydrophobic and hydrophilic functional groups in its molecule.
The hydrophilic groups of 4-n-nonylphenol can affect its adsorption by activated carbon [208,209].
Therefore, better adsorption of other micropollutants including CBZ as compared to 4-n-nonylphenol
is possible [17].
Effectiveness of GAC/PAC was also investigated at pilot-scale plants treating secondary effluent.
For instance, Ternes et al. [197] observed almost complete removal (>99%) of CBZ in a pilot-scale GAC
plant. In another study, CBZ removal was 95% in pilot-scale GAC/PAC systems treating secondary
effluent at an initial activated carbon dose of 30–100 mg/L [190]. GAC was observed to provide
better removal of PhACs including CBZ as compared to two other water treatment processes, namely,
ozonation and sand filtration [198].
Increasing activated carbon dose can improve CBZ removal. For instance, CBZ removal improved
from 36 to 97% when the PAC dose was increased seven folds [205]. In a study by Nguyen et al. [210],
instead of using PAC as a post-treatment, it was added directly to the mixed liquor of an MBR. In that
study, CBZ removal improved from 50% to 90% following the increase in PAC dose to MBR from 0.1 to
0.5 g/L [210].
Compared to GAC, PAC has a larger surface area that can conceptually provide faster reaction
kinetics and better removal efficiency. However, survey of the available literature suggests that both
GAC and PAC are effective for CBZ removal (Table 8). Notably, to date the performance of PAC and
GAC has been assessed in short term experiments [204,211]. Since saturation of binding sites reduces
the removal of pollutants over time, research is required to investigate PAC/GAC regeneration aspects.
Grover et al. [202] monitored the performance of a full-scale post-treatment GAC plant over a period
of seven months. They observed that CBZ removal reduced over time, and GAC plant could only
achieve 30% removal of CBZ during long term operation. In addition to the saturation of GAC binding
sites, impurities such as humic substances can compete for GAC/PAC binding sites that may result in
ineffective CBZ removal [4,202].
6.3. CBZ Degradation by Advanced Oxidation Processes
Due to the molecular properties of CBZ, conventional biological processes are not effective for
its removal (see Section 5). On the other hand, despite the effective removal of CBZ by NF/RO
membrane filtration and activated carbon adsorption (Tables 7 and 8), an additional step is required
for the treatment of the produced concentrate. In this context it is noteworthy that advanced oxidation
processes (AOP) may achieve effective degradation of CBZ (Table 9). Post treatment of biologically
treated wastewater by AOPs may simultaneously achieve disinfection and PhAC removal [212].
Formation of hydroxyl radicals (OH•) are mainly responsible for the degradation of PhACs
by AOPs, while formation of ozone radicals (O3•) in ozonation process can also contribute to the
degradation process [213,214]. Some PhACs such as naproxen are degraded by both OH• and
O3• radicals, while some are only susceptible to degradation by OH• radicals. CBZ, which is
resistant to biological treatment, is effectively degraded by both OH• and O3• radicals. For instance,
Ternes et al. [197] reported almost complete removal (>99%) of CBZ (35-1000 ng/L) during ozonation
process at an initial dose of 0.5 mg/L.
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Table 9. Performance of various advanced oxidation processes (AOPs) for CBZ removal.
AOP Type CBZ InitialConcentration (ng/L) Operating Conditions Removal (%) References
Ozonation
1000 Dose = 0.5 mg/LContact time = 20 min >99 [197]
35 Dose = 1-1.5 mg/LContact time = 10 min >97 [197]
9 Dose = 0.2 mg/LContact time = 15 min >99 [199]
8 × 105 Dose = 1 mg/LContact time = 10 min >99 [215]
3.8 Dose = 1.5–2 mg/LContact time = 20 min 80–99 [216]
1.18 × 105 Dose = 0.1–2 mg/LContact time = 10 h 80–99 [217]
170 Dose = 0.8 mg/LContact time = 24 min 100 [218]
4.72 × 105 Dose = 1.5–4 mg/LContact time = 20 min >99 [219]
UV alone
5000
UV Wavelength = 254 nm
Energy output = 83 W
Irradiation time = 60 min
20 [220]
NA
UV Wavelength = 200–280 nm
Energy output = 120 W
Irradiation time = NA
7 [221]
1.5 × 107
UV Wavelength = 254 nm
Energy output = 220 W
Irradiation time = 2 h
16 [222]
5 × 106
UV Wavelength = 254 nm
Energy output = 400 W
Irradiation time = 30 min
<5 [223]
19–59
UV Wavelength = 254 nm
Energy output = 10 W
Irradiation time = 3 min
<10 [224]
UV/H2O2
4.72 × 106
UV Wavelength = 254 nm
Energy output = 83 W
H2O2 dose = 170 mg/L
Irradiation time = 60 min
90 [187]
210
UV Wavelength = 254 nm
Energy output = 30 W
H2O2 dose = 2–20 mg/L
Irradiation time = 20 min
14–74 [225]
1000
UV Wavelength = 254 nm
Energy output = 20 W
H2O2 dose = 5 mg/L
Irradiation time = 15 min
60 [226]
50,000
UV Wavelength = 254 nm
Energy output = 83 W
H2O2 dose: 10–200 mg/L
Irradiation time = 60 min
90–99 [220]
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Table 9. Cont.
AOP Type CBZ InitialConcentration (ng/L) Operating Conditions Removal (%) References
19–59
UV Wavelength = 254 nm
Energy output = 10 W
H2O2 dose = 5 mg/L
Irradiation time = 3 min
20 [224]
2.36 × 105
UV Wavelength = 254 nm
Energy output = 1000 W
H2O2 dose = 5 mg/L
Irradiation time = NA
90 [227]
UV/Cl2
1000
UV Wavelength = 254 nm
Energy output = 80 W
Cl2 dose = 1 mg/L
Irradiation time = 20 min
55 [226]
19–59
UV Wavelength = 254 nm
Energy output = 10 W
Cl2 dose = 5 mg/L
Irradiation time = 1.5 min
30–60 [224]
19–59
UV Wavelength = 254 nm
Energy output = 10 W
Cl2 dose = 3 mg/L
Irradiation time = 3 min
50 [224]
UV/TiO2
4 × 106
UV Wavelength = 200–296 nm
Energy output = 1000 W
TiO2 dose = 100 mg/L
Irradiation time = 9 min
99 [228]
5 × 106
UV Wavelength = 254 nm
Energy output = 250 W
TiO2 dose = 20–500 mg/L
Irradiation time = 30 min
80–98 [223]
5 × 106
UV Wavelength = 254 nm
Energy output = 400 W
TiO2 dose = 20–500 mg/L
Irradiation time = 30 min
90–99 [223]
Photo-Fenton
5 × 107
UV Wavelength = 254 nm
Energy output = 400 W
Fe2+ dose = 5 mg/L
Irradiation time = 15 min
>99 [229]
1 × 105
UV Wavelength = 200–296 nm
Energy output = 30 W
Fe2+ dose = 5 mg/L
Irradiation time = 1.5 h
95 [230]
Note: “NA”: not available.
Although UV photlysis alone has been observed to be ineffective for CBZ removal (0–20%)
in a number of studies [220,231], removal can be significantly improved by adding H2O2 or
a photocatalyst such as TiO2 [214,220]. For instance, adding a single dose of H2O2 (5–15%) to
UV photolysis process resulted in an enhanced CBZ removal of 60–75% [225,226]. In another
study, H2O2-concentration dependent increase in CBZ removal by UV/H2O2 process was reported,
and 99% removal was achieved at an initial H2O2 concentration of 120 mg/L [220]. CBZ removal
can improve with increasing H2O2 concentration but it will reach a plateau beyond a threshold H2O2
concentration [220].
Fenton’s reagent has been reported to efficiently oxidize (>99%) CBZ (Table 9). Notably, Fe+2
based Fenton process achieved better CBZ removal than UV alone, UV/TiO2 and UV/H2O2. However,
the requirement of acidic conditions for Fenton’s process is a considerable drawback for its practical
application [232].
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AOP are undoubtedly very efficient for the removal of CBZ but their practical applications are
constrained by associated high cost of chemicals. Moreover, transformation products formed following
the oxidation of PhACs including CBZ can be more toxic than the parent compound [220]. To overcome
this issue, the use of biological filters or ACs can be a suitable option [233,234].
6.4. Combined/Hybrid Treatment Systems
A single treatment option may not be universally applicable, so a combined (sequential) or
integrated treatment may be more effective for CBZ removal. Combined or hybrid treatment options are
also conceptually beneficial, usually leading to improved treatment efficiencies [235–237]. Examples of
possible combined/hybrid water treatment processes include membrane filtration followed by
activated carbon, MBR followed by activated carbon, activated carbon adsorption followed by UV,
integrated MBR-TiO2 photocatalysis, and integrated MBR-PAC adsorption. A summary of CBZ
removal by combined/hybrid treatment systems is presented in Table 10.
Table 10. CBZ removal by combined and integrated treatment systems.
Treatment Systems
CBZ Initial
Concentration
(ng/L)
Operating Conditions Removal(%) References
Integrated
MBR-UV/TiO2
1 × 107
SRT = 60 d
HRT = 50 h
UV wavelength = 360 nm
TiO2 dose = NA
up to 95 [238]
Integrated MBR-PAC 5000
SRT = infinite
HRT = 24 h
PAC dose = 0.1 g/L
50 [210]
Integrated MBR-PAC 5000
SRT = infinite
HRT = 24 h
PAC dose = 0.5 g/L
90 [210]
Integrated Gamma
radiation-CAS (batch
experiment)
1.7 × 107 Incubation time = 10 dRadiation dose = 800 Gy >99 [239]
Integrated PAC-UF 3 × 105 PAC dose = 5–10 mg/LContact time = 1.5 h 40 [240]
Integrated MBR-PAC 7.5 × 105
SRT = infinite
HRT = 24 h
PAC dose = 0.1 and 1 g/L
34 and 90 [211]
Integrated MBR-PAC 2 × 104
SRT = infinite
HRT = 24 h
PAC dose = 1 g/L
>99 [241]
Integrated MBR-PAC 390–1800
SRT = 20 d
HRT = 24 h
PAC dose = 1 g/L
99.4 [206]
Integrated CAS-GAC 2 × 104
SRT = NA
HRT = NA
GAC dose = 100–1000 mg/L
10–50 [203]
MBR followed by GAC 5000
SRT of MBR = infinite
HRT of MBR = 24 h
GAC contact time = 7 min
98 [242]
Ozonation followed by
biological sand column 2.06
HRT of sand column = 5–6 d
Ozone contact time = NA 80 [243]
Note: NA: not available.
Kleywegt et al. [244] investigated the removal of CBZ by GAC adsorption followed by UV
photolysis that achieved effective removal of CBZ (93%). Serrano et al. [203] investigated the removal
of PhACs including CBZ in a CAS process followed by GAC adsorption. They reported that
adsorption onto activated carbon improved the overall removal of CBZ by as much as 40% [203].
Nguyen et al. [210] also reported an overall CBZ removal of 98% by an MBR followed by GAC
adsorption. When a sequencing batch reactor coupled to an external microfiltration membrane
was investigated by Serrano et al. [241], up to 93% CBZ removal was achieved following the addition
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of a single dose (1 g/L) of PAC directly into the bioreactor. Likewise, the integrated MBR-PAC system
was also reported to to achieve 92% CBZ removal [211]. CBZ removal by MBR treatment followed by
GAC filtration was investigated by Nguyen et al. [210]. While MBR alone showed a removal of less
than 20%, MBR-GAC achieved an extremely efficient removal of 98% [210]. This result demonstrates
that GAC post-treatment could significantly improve the removal of PhACs, which are resistant to
degradation by the activated sludge.
Other integrated/hybrid technologies have also shown effective CBZ removal. AOPs cannot
mineralize PhACs, however, it is important to note that the metabolites formed following the oxidation
of CBZ have been reported to be readily mineralized by the activated sludge [245–247]. For instance,
Hübner et al. [243] studied CBZ removal by combining ozonation with a sand column mimicking
a soil aquifer treatment (SAT) systems. They observed that the degradation products of CBZ formed
after ozonation were significantly mineralized (>80%) in the sand column at an HRT of 5-6 days [243].
In another study [239], a combination of gamma radiation and activated sludge based biological
treatment achieved up to 79% CBZ mineralization. They reported that significant CBZ removal (>99%)
was mainly achieved by gamma radiation at an initial dose of 800 Gy, while activated sludge was
responsible for mineralization of CBZ [239]. In a study by Laeraet al. [238], an integrated MBR-TiO2/UV
system achieved up to 95% CBZ removal from pharmaceutical industrial effluent, showing that the
integration of biological and chemical oxidation processes can be an effective strategy for enhanced
CBZ removal. Despite the efficacy of combined/integrated oxidation and biological processes for
mineralization, the cost associated with the application of oxidation processes needs to be considered.
Carbamazepine has been consistently shown to be poorly removed by coagulation despite being
a neutral compound [21,197,248–250]. However, a properly designed coagulation/flocculation unit
can efficiently remove suspended solids and can thereby enhance the performance of a subsequent
activated carbon adsorption unit by reducing competitive adsorption [151]. Coagulation pre-treatment
has been found to significantly enhance carbamazepine removal efficiency by adsorption [197].
Because high concentrations of suspended or colloidal solids in the wastewater may impede the
advanced oxidation processes, sufficient prior removal of these materials by a physicochemical
treatment such as coagulation is required [251,252].
7. Fate and Metabolites of CBZ
CBZ transformation products following its metabolism in human body or following its
degradation by different treatment processes have been reported (Figure 1). Figure 1 sheds light
on different pathways of CBZ metabolism/degradation by AOPs, human liver, and microorganisms.
Huerta-Fontela et al. [199] reported that CBZ degradation by ozonation occurs via a ring opening
mechanism due to the attack of ozone on the non-aromatic carbon-carbon double bond of CBZ,
forming the metabolite epoxy-carbamazepine. Compared to the CBZ degradation products reported
by McDowell et al. [253] in UV photolysis (Figure 1), Vogna et al. [187] observed that the addition of
H2O2 to UV photolysis yields different degradation products (Figure 1), indicating a difference in the
degradation pathway of CBZ in presence of H2O2. In biological systems (such as human liver, fungus
and activated sludge), CBZ degradation products usually contain the azepine structure (Figure 1).
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(f) activated sludge process [256].
As depicted in Figure 1, several metabolites/degradation products have been reported for
CBZ treatment by different processes. Toxicity of CBZ degradation products has been reported
in a number of studies as summarized here. Based on the Yeast Estrogen Screen (YES) assay,
Mohapatra et al. [257] reported that CBZ and its degradation products showed no estrogenic
activity. In another study, Jelic et al. [160] investigated the toxicity of the media in a pulsed
fluidized bed bioreactor containing whole-cell T. versicolor and CBZ at an initial concentration of
500 µg/L. The acute toxicity test (Microtox) showed the toxicity induced by CBZ was reduced from
95% to 24% after an incubation time of 10 days, suggesting that the degradation products were
non-toxic [258]. Similarly, degradation products following the oxidation of CBZ by ozonation, UV
and UV/H2O2 processes exhibited no genotoxic, cytotoxic or estrogenic effects [258]. CBZ metabolites
including 10,11-dihydro-trans-10,11-dihydroxy-carbamazepine, acidone and acridine formed during
CAS process [256] have also been reported to be non-toxic [258,259]. Although degradation products
or metabolites of CBZ formed during CAS and AOPs are non-toxic, Bu et al. [255] reported that
CBZ-2,3-arene (one oxide intermediate) is believed to cause idiosyncratic effect after CBZ consumption
for medicinal purposes [255].
8. Conclusions and Outlook
Although its occurrence in freshwater may not pose an immediate threat to aquatic ecosystems or
human health, effective removal of CBZ is still required for safe water reuse applications and drinking
water treatment. Biological wastewater treatment processes such as conventional activated sludge
and membrane bioreactor are not effective for CBZ removal due to its resistance to biodegradation.
However, advanced wastewater treatment processes seem to be effective for efficient CBZ removal.
For instance, CBZ removal by the reverse osmosis and nanofiltration membranes is above 90%.
Similarly, post-treatment with granular and powdered activated carbon provides efficient CBZ removal
ranging from 90–99%. However, membrane fouling in case of membrane technologies and regeneration
of activated carbon are obstacles that warrant technical solutions. Depending on the type of fungal
Water 2018, 10, 107 19 of 32
species and operating condition, white-rot fungi can achieve almost complete removal of CBZ but
bacterial contamination may affect the efficacy of fungal bioreactors during long term operations.
Although advanced oxidation processes such as ozonation, UV/H2O2, UV/TiO2 and Fenton processes
are effective for CBZ removal, costs associated with the addition of chemicals, and separation of
catalysts needs to be carefully considered. Finally, the literature to date suggests that degradation
products formed following the degradation of CBZ by biological and chemical oxidation processes
may not induce toxic effects on aquatic ecosystems.
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